Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:80909 |
Name | castration-resistant prostate carcinoma |
Definition | A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer male reproductive organ cancer prostate cancer prostate carcinoma castration-resistant prostate carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PTEN loss | Abiraterone + Ipatasertib | castration-resistant prostate carcinoma | sensitive | detail... |
PTEN loss | Enzalutamide + GSK2636771 | castration-resistant prostate carcinoma | no benefit | detail... |
PTEN inact mut | CC-115 + Enzalutamide | castration-resistant prostate carcinoma | predicted - sensitive | detail... |
PIK3CA act mut | CC-115 + Enzalutamide | castration-resistant prostate carcinoma | predicted - sensitive | detail... |
TSC1 loss | CC-115 + Enzalutamide | castration-resistant prostate carcinoma | predicted - sensitive | detail... |
TSC2 loss | CC-115 + Enzalutamide | castration-resistant prostate carcinoma | predicted - sensitive | detail... |
PTEN N323fs | Everolimus | castration-resistant prostate carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03436485 | Phase Ib/II | ODM-208 | Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer (CYPIDES) | Recruiting | USA | GBR | FRA | 1 |
NCT03903835 | Phase III | Docetaxel Cabazitaxel Carboplatin Abiraterone Enzalutamide | ProBio: A Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (ProBio) | Recruiting | BEL | 3 |
NCT04434482 | Phase I | Senaparib + Temozolomide | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | Recruiting | USA | AUS | 3 |
NCT04839991 | Phase I | CB307 | Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours. (POTENTIA) | Recruiting | USA | GBR | ESP | 1 |
NCT04926181 | Phase II | Apalutamide + Cetrelimab | Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer | Active, not recruiting | USA | 0 |
NCT04946370 | Phase Ib/II | Pembrolizumab 225Ac-J591 + Pembrolizumab | Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC | Recruiting | USA | 0 |
NCT05005728 | Phase II | XmAb20717 Olaparib + XmAb20717 Cabazitaxel + Carboplatin + XmAb20717 | XmAb20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT05057013 | Phase Ib/II | HMBD-001 | HMBD-001 in Advanced HER3 Positive Solid Tumours | Recruiting | GBR | 0 |
NCT05107674 | Phase I | NX-1607 | A Study of NX-1607 in Adults With Advanced Malignancies | Recruiting | USA | GBR | 0 |
NCT05159518 | Phase I | PRT2527 | A Study of PRT2527 in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT05241613 | Phase I | AC176 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT05256381 | Phase II | Pembrolizumab + SOT101 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | BEL | 2 |
NCT05369000 | Phase Ib/II | LAVA-1207 | Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT05488548 | Phase I | NEO2734 | Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05501548 | Phase II | Olaparib | Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT05534646 | Phase II | Apalutamide Apalutamide + Carotuximab | Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT05592626 | Phase Ib/II | STAR0602 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) | Recruiting | USA | CAN | 0 |
NCT05662397 | Phase Ib/II | HST-1011 Cemiplimab + HST-1011 | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | Recruiting | USA | 0 |
NCT05689021 | Phase II | Niraparib and abiraterone acetate + Prednisone | CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations | Recruiting | USA | 0 |
NCT05700669 | Phase Ib/II | AsiDNA + Olaparib | Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors | Recruiting | USA | 0 |
NCT05730712 | Phase II | Enzalutamide + Pertuzumab/trastuzumab/hyaluronidase-zzxf | Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer, TraPPer Study | Not yet recruiting | USA | 0 |
NCT05785741 | Phase Ib/II | DB-1310 | A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05914116 | Phase Ib/II | DB-1311 | A Study of DB-1311 in Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05917470 | Phase Ib/II | ONCT-534 | A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. | Recruiting | USA | 0 |
NCT05999968 | Phase I | Abemaciclib + Darolutamide | Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment | Not yet recruiting | USA | ESP | DEU | 0 |
NCT06039371 | Phase II | Etoposide + Testosterone cypionate Carboplatin + Testosterone cypionate | Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study | Not yet recruiting | USA | 0 |
NCT06126731 | Phase Ib/II | Amoxicillin + Enzalutamide + Metronidazole Ciprofloxacin + Enzalutamide + Vancomycin | Combination Study of Antibiotics With Enzalutamide (PROMIZE) | Recruiting | GBR | 1 |